Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.45 - $3.48
Previous CloseN/A
Volume12.23K
Average Volume (3M)108.02K
Market Cap
$52.41M
Enterprise Value$381.57M
Total Cash (Recent Filing)$4.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 07, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding33,809,708
10 Day Avg. Volume178,434
30 Day Avg. Volume108,016
Financial Highlights & Ratios
PEG Ratio4.50
Price to Book (P/B)-101.46
Price to Sales (P/S)0.00
P/FCF Ratio-1.73K
Enterprise Value/Market Cap7.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$8.00Price Target Upside406.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
HeartBeam News
PremiumTipRanks Newswire
HeartBeam (NASDAQ: BEAT) Is ‘One to Watch’
PremiumCompany Announcements
HeartBeam’s Positive Earnings Call Reflects Growth Potential
PremiumCompany Announcements
HeartBeam, Inc. Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalHeartBeam's proprietary system for arrhythmia assessment received 510(k) clearance from the FDA.
Strategic PartnershipsA strategic collaboration was signed with AccurKardia to add AccurECG™ algorithm to HeartBeam’s device, facilitating quicker diagnosis and faster access to clinical care.
Technological AdvancementsThe company's proprietary, cable-free 12 lead ECG system captures heart signals in three dimensions, providing highly accurate diagnosis of a range of conditions.
Bears Say
Commercial Launch TimingHeartBeam is well prepared for a pilot commercial launch and a full launch in 2026.
Financial PerformanceCash used in operating activities was $4.5M, indicating significant expenses in the first quarter.
Options Prices
Currently, No data available
---
Ownership Overview
15.36% Insiders
3.05% Mutual Funds
2.81% Other Institutional Investors
76.13% Public Companies and
Individual Investors
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $1.45 and its highest was $3.48 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $52.41M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Aug 07, 2025 which is in 48 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on May 13, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.03.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.16.
How many shares outstanding does HeartBeam have?
HeartBeam has 33,809,708 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -6.433%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
HeartBeam Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (406.33% Upside)
$8.00 (406.33% Upside)
Blogger Sentiment
Bullish
BEAT Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $80.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.39%
12-Months-Change
Fundamentals
Return on Equity
-202.58%
Trailing 12-Months
Asset Growth
-33.21%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements in regulatory approvals, strategic collaborations, and commercial readiness efforts. While there are challenges related to financial constraints and dependencies on partnerships, the company's progress and strategic planning position it well for future commercialization and growth.Read More>BEAT Stock 12 Month Forecast
Average Price Target
$8.00
▲(406.33%Upside)